Arca
Skip to content
Tools
Tools

Uveitis

Drug research and approvals for uveitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 45 studies of uveitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 5 approved and 8 open orphan designations naming it.

  • Recruiting worldwide: 45
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 5
  • EU medicines: 0

Recruiting now

Newest start dates first, of 45 recruiting on ClinicalTrials.gov ↗

Drug pipeline

5 approved, 11 in phase 3, 16 in phase 2, 8 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Adalimumab, Fluocinolone acetonide, Methylprednisolone acetate, Prednisolone phosphoric acid, Dexamethasone

Prednisone
Phase 3 Glucocorticoid receptor agonist
Secukinumab
Phase 3 Interleukin 17A inhibitor
Methotrexate
Phase 3 Dihydrofolate reductase inhibitor
Gevokizumab
Phase 3 Interleukin-1 beta negative allosteric modulator
Mycophenolate mofetil
Phase 3 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Baricitinib
Phase 3 Tyrosine-protein kinase JAK1 inhibitor
Difluprednate
Phase 3 Glucocorticoid receptor agonist
Voclosporin
Phase 3 Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
Bevacizumab
Phase 3 Vascular endothelial growth factor A inhibitor
Triamcinolone acetonide
Phase 3 Glucocorticoid receptor agonist
Prednisolone acetate
Phase 3 Glucocorticoid receptor agonist
Daclizumab
Phase 2 Interleukin-2 receptor inhibitor
Tocilizumab
Phase 2 Interleukin-6 receptor alpha subunit inhibitor
Simvastatin
Phase 2 HMG-CoA reductase inhibitor
Ustekinumab
Phase 2 Interleukin-12 inhibitor
Izokibep
Phase 2 Interleukin 17A inhibitor
Everolimus
Phase 2 FK506-binding protein 1A inhibitor
Leflunomide
Phase 2 Dihydroorotate dehydrogenase inhibitor
Basiliximab
Phase 2 Interleukin-2 receptor inhibitor
Sarilumab
Phase 2 Interleukin-6 receptor alpha subunit antagonist
Anakinra
Phase 2 Interleukin-1 receptor antagonist
Corticotropin
Phase 2 Melanocortin receptor 2 agonist
Abatacept
Phase 2 T-lymphocyte activation antigen CD86 inhibitor
Fingolimod
Phase 2 Sphingosine 1-phosphate receptor agonist
Filgotinib
Phase 2 Tyrosine-protein kinase JAK1 inhibitor
Folic acid
Phase 2
Leucovorin
Phase 2
Cyclosporine
Phase 1 Cyclophilin A modulator
Ocriplasmin
Phase 1 Fibronectin proteolytic enzyme
Interferon GAMMA-1B
Phase 1 Interferon gamma receptor agonist

Showing the 30 furthest along of 35 in trials.

How its trials ended

337 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 94 whose ending is known, 39% met their primary endpoint, 0% missed it and 61% stopped early.

  • Completed, result not reported14543%
  • Ongoing5015%
  • Status unknown4814%
  • Met its primary endpoint3711%
  • Stopped: other or unclear3510%
  • Stopped: enrollment or feasibility93%
  • Stopped: sponsor or business decision72%
  • Stopped: lack of efficacy51%
  • Stopped: safety10%

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 3, 2026A phase 2b, randomized, double-masked, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with active noninfectious…MK-7240 (tulisokibart) / PrednisoneMerck & Co. (MSD)Pending
Nov 1, 2019Adalimumab vs conventional immunosuppression for uveitis (ADVISE) trialHumira (adalimumab) / Imuran (azathioprine) / Neoral (cyclosporine) /…Johns Hopkins Bloomberg School of Public HealthPending
Jul 25, 2013A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate,…GevokizumabServierOngoing

FDA orphan designations

Approved first, then open designations, newest first
Sep 28, 2018HumiraTreatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and olderAbbVie, Inc.Approved
Jun 30, 2016HumiraIndicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patientsAbbVie, Inc.Approved
Jun 13, 2012DurezolTreatment of endogenous anterior uveitisAlcon Pharmaceuticals. Ltd.Approved
Sep 24, 2010OzurdexFor treatment of non-infectious uveitis affecting the posterior segment of the eyeAllerganApproved
Apr 8, 2005RetisertTreatment of chronic non-infectious uveitis affecting the posterior segment of the eyeBausch & Lomb Pharmaceuticals, Inc.Approved
Oct 4, 2023MethotrexateTreatment of non-infectious intermediate, posterior, or pan uveitis or chronic non-infectious anterior uveitisNordic Group B.V.Designated
Jun 22, 2022AAV2.adalimumabTreatment of non-infectious intermediate, posterior, or panuveitis or chronic non-infectious anterior uveitisKriya Therapeutics, Inc.Designated
Dec 7, 2021TacrolimusTreatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitisBioNanoSim Ltd.Designated
Jun 3, 2019Ac-Nle-cyclo-(Glu-His-D-Phe-Arg-Dap)-Trp-NH2Treatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitisPalatin Technologies, Inc.Designated
Nov 4, 2011SirolimusTreatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and…Santen Inc.Designated
Dec 20, 2006Cyclo…Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitisLux Biosciences, Inc.Designated
Jan 16, 2003Human Anti-tumor Necrosis factor alpha monoclonal antibodyTreatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology…Centocor, Inc.Designated
Oct 8, 1992Ai-rsaTreatment of autoimmune uveitis.AutoImmune, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.